FIELD: pharmaceutics.
SUBSTANCE: invention relates to a liquid pharmaceutical composition containing from 0.05 mg/ml to 0.5 mg/ml of carbetocinum or its pharmaceutically active salt. pH value of the composition ranges from 5.1 to 5.9. Composition may additionally contain a buffer agent, an antioxidant and an agent for maintaining isotonicity. Liquid pharmaceutical composition containing from 0.01 to 4 mg/ml of pharmaceutically active compound FE 202767 or its pharmaceutically acceptable salt is also described. pH value of the composition ranges from 5.1 to 5.9. Kits containing said liquid pharmaceutical compositions are also described.
EFFECT: pharmaceutical compositions have improved stability.
22 cl, 7 dwg, 7 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2737264C2 |
| ORALLY DISINTEGRATING SOLID PHARMACEUTICAL DOSAGE UNIT CONTAINING A GENERIC ACTIVITY CONTROLLING SUBSTANCE | 2015 |
|
RU2719416C2 |
| ORALLY DISINTEGRATING SOLID PHARMACEUTICAL DOSAGE UNIT CONTAINING PARTUS CONTROL SUBSTANCE | 2015 |
|
RU2701199C2 |
| COMPOSITIONS CONTAINING ANAKINRA | 2016 |
|
RU2728795C2 |
| LIQUID FORMULATION OF LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2013 |
|
RU2671576C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING PALANOSETRON AS AN ACTIVE INGREDIENT | 2017 |
|
RU2732407C1 |
| PHARMACEUTICAL PREPARATION CONTAINING EGF RECEPTOR ANTIBODY | 2004 |
|
RU2381036C2 |
| CITRATE FREE PHARMACEUTICAL COMPOSITIONS COMPRISING ANAKINRA | 2012 |
|
RU2599848C2 |
| INTERFERON AN AQUEOUS SOLUTION | 1996 |
|
RU2113845C1 |
| LIQUID COMPOSITION OF HUMAN GROWTH HORMONE WITH PROLONGED ACTION | 2011 |
|
RU2623026C2 |
